Online Table O1 Baseline Characteristics of study sample and comparison with all eligible participants

| Baseline Chara | cteristic | Methacholine test at follow-up, complete covariate data & no asthma medication (n=3005) | Only baseline methacholine test, although eligible for testing at follow-up (n=3127)* | Only baseline spirometry, but no methacholine test due to technical problems, refusal or medical exclusion (n=2084)* | p-Value p-Value comparing comparing I and II** I and III** |
|---|---------------------------|---|---|--|--|
| Female sex | (%) | 49.1 | 50.7 | 55.9 | 0.219 <0.001 |
| Age | (mean/sd) | 39.1 / 11 | 40.3 / 11.9 | 44.1 / 11.6 | <0.001 <0.001 |
| Phadiatop test | (%) | 29.4 | 28.7 | 28.2 | 0.564 0.397 |
| Exposure to ETS never smoker (%) | | 13.2 | 13.3 | 12.5 | 0.993 0.415 |
| Exposure to ETS ex-smoker (%) | | 6.9 | 7.6 | 7.9 | 0.292 0.192 |
| BMI in kg/m ² | (median/1st/3rd quartile) | 23.0 / 21 / 25 | 23.4 / 21.2 / 26.2 | 23.8 / 21.4 / 26.8 | 0.01 <0.001 |
| Current smoking | ng (%) | 28.3 | 37.5 | 34.1 | <0.001 <0.001 |
| Ex-smoking | (%) | 23.5 | 21.6 | 22.6 | 0.088 0.442 |
| Packyears | (median/1st/3rd quartile) | 11.4 / 4 / 23 | 14 / 5.2 / 27.9 | 17.0 / 6.0 / 32.8 | <0.001 <0.001 |
| FEV1 in litres | (median/1st/3rd quartile) | 3.7 / 3.1 / 4.3 | 3.5 / 3 / 4.2 | 3.1 / 2.6 / 3.7 | <0.001 <0.001 |
| FEF ₂₅₋₇₅ in ml/sec(median/1st/3rd quartile) | | 3.5 / 2.7 / 4.4 | 3.4 / 2.7 / 4.3 | 2.9 / 2.0 / 3.8 | <0.001 <0.001 |
| FVC in litres | (median/1st/3rd quartile) | 4.6 / 3.9 / 5.4 | 4.4 / 3.7 / 5.2 | 4.1 / 3.5 / 4.9 | <0.001 <0.001 |
| Doctor's diagno | osed asthma (%) | 3.7 | 6.6 | 7.9 | <0.001 <0.001 |
| Being hyper-reactive (%) | | 12.9 | 18.2 | 24.9 | <0.001 <0.001 |
| Reactivity slope (median/1st/3rd quartile) | | 1.0 / 0.6 / 1.7 | 1.08 / 0.59 / 1.96 | | <0.001 |
| Wheezing without cold in the last year(%) | | 4.4 | 8.1 | 11.2 | <0.001 <0.001 |
| Chronic cough | (%) | 3.0 | 5.2 | 7.5 | <0.001 <0.001 |

^{*} smaller sample sizes for packyears because relating to ever-smokers (n=1794 in group II, n=1130 in group III)
** T-tests for means, Wilcoxon rank sum tests for medians, Chi-2 tests for proportions

Online table O2 Airway hyper-reactivity at baseline and follow-up examination

| Baseline | Follow-up Examination | | | | |
|---------------------|------------------------------|---------------------|-------|------------------------------|--|
| Examination | | | | | |
| | normoreactive hyper-reactive | | Total | | |
| | | | | | |
| normoreactive n(%) | 2684 (93.2) | 195 (6.8) | 2879 | | |
| % of total | 79.9 | 5.8 | 85.7 | | |
| | | | | | |
| hyper-reactive n(%) | 255 (53.2) | 224 (46.8) | 479 | | |
| % of total | 7.6 | 6.7 | 14.3 | | |
| | | | | p _{McNemar} =0.0054 | |
| Total n(%) | 2939 (87.5) | 419 (12.5) | 3358 | • | |
| | | | | | |
| | | | | | |

Online table O3 Influence of adjustment for lung function on effect estimates for change in bronchial reactivity slope of other model covariates

| | Main Model ¹⁾ | Model with absolute change ²⁾ | Model without lung function variables ³⁾ | Model with %- predicted lung function and change ⁴⁾ | |
|-----------------------------------|--------------------------|--|---|---|--|
| Covariate | % change in b.r. slope | %-change in b.r. slope | %-change in b.r. slope | %-change in b.r. slope (95%-CI) | |
| Covariate | (95%-CI) | (95%-CI) | (95%-CI) | | |
| | -3.9 | - 10.9 | -13.1* | -13.8* | |
| Female sex | (-21.1 to 16.9) | (-27.8 to 9.9) | (-21.5 to -3.7) | (-22.4 to -4.2) | |
| | 0.9* | 0.6 | 0.8* | 0.7* | |
| Age (centered at 40 years) | (0.4 to 1.5) | (-0.1 to 1.2) | (0.3 to 1.3) | (0.2 to 1.3) | |
| • | 0.05* | 0.05* | 0.04* | 0.04* | |
| Age(centered at 40 years) squared | (0.01 to 0.09) | (0.01 to 0.09) | (0.00 to 0.08) | (0.00 to 0.08) | |
| ETS in never | -1.0 | -0.3 | -1.0 | -1.0 | |
| smokers | (-16.0 to 16.7) | (-15.5 to 17.6) | (-16.0 to 16.7) | (-16.0 to 16.7) | |
| | 10.7 | 8.6 | 10.3 | 9.5 | |
| ETS in ex-smokers | (-10.1 to 36.3) | (-11.8 to 33.7) | (-10.4 to 35.8) | (-11.1 to 34.8) | |
| | -6.3 | -6.7 | -6.5 | -7.2 | |
| Atopy | (-15.8 to 4.2) | (-16.1 to 3.8) | (-16.0 to 4.1) | (-16.6 to 3.2) | |
| BMI (centered at | -0.1 | -0.1 | -0.2 | -0.1 | |
| 25 kġ/m²) | (-1.6 to 1.4) | (-1.6 to 1.5) | (-1.6 to 1.3) | (-1.6 to 1.4) | |
| Change** in | 2.7* | 2.4 | 2.7* | 2.5* | |
| centered BMI | (0.3 to 5.2) | (0.0 to 4.9) | (0.3 to 5.2) | (0.1 to 4.9) | |
| | 21.2* | 19.1* | 21.0* | 19.2* | |
| Smoking | (7.5 to 36.7) | (5.4 to 34.6) | (7.3 to 36.5) | (5.5 to 34.6) | |
| | -5.1 | -4.7 | -4.8 | -5.3 | |
| Ex-smoking | (-18.2 to 10.1) | (-17.9 to 10.6) | (-17.9 to 10.4) | (-18.4 to 9.8) | |
| FEV1 percent | | | | -0.1 | |
| predicted | | | | (-0.8 to 0.6) | |
| Change** in FEV1 | | | | -1.2* | |
| percent predicted | | | | (-2.1 to -0.4) | |
| FVC percent | | | | 0.2 | |
| predicted | | | | (-0.4 to 0.9) | |
| Change** FVC | | | | 0.4 | |
| percent predicted | ativita valana da C | | in FF)// | (-0.4 to 1.2) | |

b.r. slope: bronchial reactivity slope, defined as percent change in FEV1 per umol methacholine

¹⁾ Estimates from a mixed linear model and adjusted for all covariates with estimates in the table plus baseline FEV1 (centered at 3.5L), baseline FVC (centered at 5L), baseline FEF25-75 (adjusted for sex and FEV1 and centered at its mean), presence of concurrent colds at both examinations, seasonal terms, and random effects for area

²⁾ Model with all covariates form model 1 plus change in centered FEV1, FVC and FEF²⁵⁻⁷⁵ variables (calculated as follow-up minus baseline value)

3) Model including just the covariates with estimates in the table

⁴⁾ Model including covariates as listed in the table and adjustment for FEV1 and FVC %-predicted (using ECTS prediction equations) and change in %-predicted values (calculated as follow-up minus baseline value)

significant at 5% threshold

^{**} change was calculated as follow-up minus baseline value